Skip to main content
SpringerLink
Log in

Methicillin-Resistant Staphylococcus aureus Infection and Treatment Options

  • Protocol
  • First Online:
Methicillin-Resistant Staphylococcus Aureus (MRSA) Protocols

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2069))

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of infection worldwide, including a wide array of both hospital- and community-acquired infections—most commonly bacteremia, upper and lower respiratory tract infection, skin and soft-tissue infection, osteomyelitis, and septic arthritis. This chapter describes the epidemiology of MRSA infection, its ability to confer antibiotic resistance and produce a wide array of virulence factors, and its pivotal role in human infection, especially cystic fibrosis. It also provides an introduction to the strategies for treatment of both chronic and acute MRSA infections.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ogston A (1881) Report upon micro-organisms in surgical diseases. Br Med J 1(1054):369.b2–375

    Article  PubMed  PubMed Central  Google Scholar 

  2. Jarraud S, Mougel C, Thioulouse J, Lina G, Meugnier H, Forey F et al (2002) Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect Immun 70(2):631–641

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lee AS, de Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, Peschel A et al (2018) Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers 4:18033

    Article  PubMed  Google Scholar 

  4. Shopsin B, Drlica-Wagner A, Mathema B, Adhikari RP, Kreiswirth BN, Novick RP (2008) Prevalence of agr dysfunction among colonizing Staphylococcus aureus strains. J Infect Dis 198(8):1171–1174

    Article  PubMed  Google Scholar 

  5. Smyth DS, Kafer JM, Wasserman GA, Velickovic L, Mathema B, Holzman RS et al (2012) Nasal carriage as a source of agr-defective Staphylococcus aureus bacteremia. J Infect Dis 206(8):1168–1177

    Article  PubMed  PubMed Central  Google Scholar 

  6. Painter KL, Krishna A, Wigneshweraraj S, Edwards AM (2014) What role does the quorum-sensing accessory gene regulator system play during Staphylococcus aureus bacteremia? Trends Microbiol 22(12):676–685

    Article  CAS  PubMed  Google Scholar 

  7. Harkins CP, Pichon B, Doumith M, Parkhill J, Westh H, Tomasz A et al (2017) Methicillin-resistant Staphylococcus aureus emerged long before the introduction of methicillin into clinical practice. Genome Biol 18:130

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jevons MP (1961) “Clabbering” – resistant Staphylococci. Br Med J 1(5219):124–125

    Article  PubMed Central  Google Scholar 

  9. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN et al (2001) Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 32(Suppl 2):S114–S132

    Article  CAS  PubMed  Google Scholar 

  10. Styers D, Sheehan DJ, Hogan P, Sahm DF (2006) Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 5:2

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Prevention CfDCa (2012) Active bacterial core surveillance report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2011. http://www.cdc.gov/abcs/reports-findings/survreports/mrsa11.pdf.

  12. Calfee DP, Salgado CD, Milstone AM, Harris AD, Kuhar DT, Moody J et al (2014) Strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 35(Suppl 2):S108–S132

    Article  PubMed  Google Scholar 

  13. Huang SS, Septimus E, Platt R (2013) Targeted decolonization to prevent ICU infections. N Engl J Med 369(15):1470–1471

    CAS  PubMed  Google Scholar 

  14. Nimmo GR, Bell JM, Mitchell D, Gosbell IB, Pearman JW, Turnidge JD et al (2003) Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals, 1989–1999. Microb Drug Resist 9(2):155–160

    Article  CAS  PubMed  Google Scholar 

  15. Morrison MA, Hageman JC, Klevens RM (2006) Case definition for community-associated methicillin-resistant Staphylococcus aureus. J Hosp Infect 62(2):241

    Article  CAS  PubMed  Google Scholar 

  16. Cuny C, Wieler LH, Witte W (2015) Livestock-associated MRSA: the impact on humans. Antibiotics (Basel) 4(4):521–543

    Article  CAS  Google Scholar 

  17. Cuny C, Kock R, Witte W (2013) Livestock associated MRSA (LA-MRSA) and its relevance for humans in Germany. Int J Med Microbiol 303(6–7):331–337

    Article  PubMed  Google Scholar 

  18. Chambers HF, Deleo FR (2009) Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7(9):629–641

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Purrello SM, Daum RS, Edwards GFS, Lina G, Lindsay J, Peters G et al (2014) Meticillin-resistant Staphylococcus aureus (MRSA) update: new insights into bacterial adaptation and therapeutic targets. J Glob Antimicrob Resist 2(2):61–69

    Article  CAS  PubMed  Google Scholar 

  20. Wu S, Piscitelli C, de Lencastre H, Tomasz A (1996) Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of mecA from a methicillin susceptible strain of Staphylococcus sciuri. Microb Drug Resist 2(4):435–441

    Article  CAS  PubMed  Google Scholar 

  21. Shore AC, Deasy EC, Slickers P, Brennan G, O'Connell B, Monecke S et al (2011) Detection of staphylococcal cassette chromosome mec type XI carrying highly divergent mecA, mecI, mecR1, blaZ, and ccr genes in human clinical isolates of clonal complex 130 methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55(8):3765–3773

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Li S, Skov RL, Han X, Larsen AR, Larsen J, Sorum M et al (2011) Novel types of staphylococcal cassette chromosome mec elements identified in clonal complex 398 methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 55(6):3046–3050

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bal AM, Coombs GW, Holden MTG, Lindsay JA, Nimmo GR, Tattevin P et al (2016) Genomic insights into the emergence and spread of international clones of healthcare-, community- and livestock-associated meticillin-resistant Staphylococcus aureus: blurring of the traditional definitions. J Glob Antimicrob Resist 6:95–101

    Article  CAS  PubMed  Google Scholar 

  24. Reynolds PE (1989) Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 8(11):943–950

    Article  CAS  PubMed  Google Scholar 

  25. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40(1):135–136

    Article  CAS  PubMed  Google Scholar 

  26. Gardete S, Tomasz A (2014) Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest 124(7):2836–2840

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC (2008) Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006. Clin Infect Dis 46(5):668–674

    Article  CAS  PubMed  Google Scholar 

  28. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP et al (2003) Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348(14):1342–1347

    Article  PubMed  Google Scholar 

  29. Berglund C, Prevost G, Laventie BJ, Keller D, Soderquist B (2008) The genes for Panton Valentine Leukocidin (PVL) are conserved in diverse lines of methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Microbes Infect 10(8):878–884

    Article  CAS  PubMed  Google Scholar 

  30. Kluytmans J, van Belkum A, Verbrugh H (1997) Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 10(3):505–520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wunderink RG, Yin Y (2016) Antibiotic resistance in community-acquired pneumonia pathogens. Semin Respir Crit Care Med 37(6):829–838

    Article  PubMed  Google Scholar 

  32. Kuehnert MJ, Kruszon-Moran D, Hill HA, McQuillan G, McAllister SK, Fosheim G et al (2006) Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001–2002. J Infect Dis 193(2):172–179

    Article  CAS  PubMed  Google Scholar 

  33. Eriksen NH, Espersen F, Rosdahl VT, Jensen K (1995) Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiol Infect 115(1):51–60

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Stenehjem E, Rimland D (2013) MRSA nasal colonization burden and risk of MRSA infection. Am J Infect Control 41(5):405–410

    Article  PubMed  Google Scholar 

  35. von Eiff C, Becker K, Machka K, Stammer H, Peters G (2001) Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 344(1):11–16

    Article  Google Scholar 

  36. Jarvis WR, Jarvis AA, Chinn RY (2012) National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at United States health care facilities, 2010. Am J Infect Control 40(3):194–200

    Article  PubMed  Google Scholar 

  37. Xiao G, Chen Z, Lv X (2018) Chlorhexidine-based body washing for colonization and infection of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: an updated meta-analysis. Infect Drug Resist 11:1473–1481

    Article  PubMed  PubMed Central  Google Scholar 

  38. Emonts M, Uitterlinden AG, Nouwen JL, Kardys I, Maat MP, Melles DC et al (2008) Host polymorphisms in interleukin 4, complement factor H, and C-reactive protein associated with nasal carriage of Staphylococcus aureus and occurrence of boils. J Infect Dis 197(9):1244–1253

    Article  CAS  PubMed  Google Scholar 

  39. Krismer B, Weidenmaier C, Zipperer A, Peschel A (2017) The commensal lifestyle of Staphylococcus aureus and its interactions with the nasal microbiota. Nat Rev Microbiol 15:675

    Article  CAS  PubMed  Google Scholar 

  40. Uehara Y, Nakama H, Agematsu K, Uchida M, Kawakami Y, Abdul Fattah AS et al (2000) Bacterial interference among nasal inhabitants: eradication of Staphylococcus aureus from nasal cavities by artificial implantation of Corynebacterium sp. J Hosp Infect 44(2):127–133

    Article  CAS  PubMed  Google Scholar 

  41. Sai N, Laurent C, Strale H, Denis O, Byl B (2015) Efficacy of the decolonization of methicillin-resistant Staphylococcus aureus carriers in clinical practice. Antimicrob Resist Infect Control 4:56

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Houck PW, Nelson JD, Kay JL (1972) Fatal septicemia due to Staphylococcus aureus 502A. Report of a case and review of the infectious complications of bacterial interference programs. Am J Dis Child 123(1):45–48

    Article  CAS  PubMed  Google Scholar 

  43. van Rijen M, Bonten M, Wenzel R, Kluytmans J (2008) Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 4:Cd006216

    Google Scholar 

  44. Hart D (1937) Operation room infections: control of air-borne pathogenic organisms, with particular reference to the use of special bactericidal radiant energy; preliminary report. Arch Surg 34(5):874–896

    Article  Google Scholar 

  45. Hallman FA (1937) Pathogenic staphylococci in the anterior nares: their incidence and differentiation. Proc Soc Exp Biol Med 36(5):789–794

    Article  Google Scholar 

  46. McKinnell JA, Huang SS, Eells SJ, Cui E, Miller LG (2013) Quantifying the impact of extranasal testing of body sites for methicillin-resistant Staphylococcus aureus colonization at the time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol 34(2):161–170

    Article  PubMed  Google Scholar 

  47. Poovelikunnel TT, Gethin G, Solanki D, McFadden E, Codd M, Humphreys H (2018) Randomized controlled trial of honey versus mupirocin to decolonize patients with nasal colonization of meticillin-resistant Staphylococcus aureus. J Hosp Infect 98(2):141–148

    Article  CAS  PubMed  Google Scholar 

  48. Tilahun B, Faust AC, McCorstin P, Ortegon A (2015) Nasal colonization and lower respiratory tract infections with methicillin-resistant Staphylococcus aureus. Am J Crit Care 24(1):8–12

    Article  PubMed  Google Scholar 

  49. Boris M, Sellers TF Jr, Eichenwald HF, Ribble JC, Shinefield HR (1964) Bacterial interference; protection of adults against nasal Staphylococcus aureus infection after colonization with a heterologous S aureus strain. Am J Dis Child 108:252–261

    Article  CAS  PubMed  Google Scholar 

  50. Kiefer A, Bogdan C, Melichar VO (2018) Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme. BMC Pulm Med 18(1):20

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Chan JD, Dellit TH, Choudhuri JA, McNamara E, Melius EJ, Evans HL et al (2012) Active surveillance cultures of methicillin-resistant Staphylococcus aureus as a tool to predict methicillin-resistant S. aureus ventilator-associated pneumonia. Crit Care Med 40(5):1437–1442

    Article  PubMed  Google Scholar 

  52. Langsjoen J, Brady C, Obenauf E, Kellie S (2014) Nasal screening is useful in excluding methicillin-resistant Staphylococcus aureus in ventilator-associated pneumonia. Am J Infect Control 42(9):1014–1015

    Article  PubMed  Google Scholar 

  53. Carr AL, Daley MJ, Givens Merkel K, Rose DT (2018) Clinical utility of methicillin-resistant Staphylococcus aureus nasal screening for antimicrobial stewardship: a review of current literature. Pharmacotherapy 38:1216

    Article  CAS  PubMed  Google Scholar 

  54. Acuna-Villaorduna C, Branch-Elliman W, Strymish J, Gupta K (2017) Active identification of patients who are methicillin-resistant Staphylococcus aureus colonized is not associated with longer duration of vancomycin therapy. Am J Infect Control 45(10):1081–1085

    Article  PubMed  Google Scholar 

  55. Sarikonda KV, Micek ST, Doherty JA, Reichley RM, Warren D, Kollef MH (2010) Methicillin-resistant Staphylococcus aureus nasal colonization is a poor predictor of intensive care unit-acquired methicillin-resistant Staphylococcus aureus infections requiring antibiotic treatment. Crit Care Med 38(10):1991–1995

    Article  PubMed  Google Scholar 

  56. Chaberny IF, Schwab F, Ziesing S, Suerbaum S, Gastmeier P (2008) Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted time-series analysis. J Antimicrob Chemother 62(6):1422–1429

    Article  CAS  PubMed  Google Scholar 

  57. Clancy M, Graepler A, Wilson M, Douglas I, Johnson J, Price CS (2006) Active screening in high-risk units is an effective and cost-avoidant method to reduce the rate of methicillin-resistant Staphylococcus aureus infection in the hospital. Infect Control Hosp Epidemiol 27(10):1009–1017

    Article  PubMed  Google Scholar 

  58. Jang HC, Choi OJ, Kim GS, Jang MO, Kang SJ, Jung SI et al (2014) Active surveillance of the trachea or throat for MRSA is more sensitive than nasal surveillance and a better predictor of MRSA infections among patients in intensive care. PLoS One 9(6):e99192

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Metersky ML, Kalil AC (2017) New guidelines for nosocomial pneumonia. Curr Opin Pulm Med 23(3):211–217

    Article  PubMed  Google Scholar 

  60. Epstein L, Mu Y, Belflower R, Scott J, Ray S, Dumyati G et al (2016) Risk factors for invasive methicillin-resistant Staphylococcus aureus infection after recent discharge from an acute-care hospitalization, 2011–2013. Clin Infect Dis 62(1):45–52

    Article  PubMed  Google Scholar 

  61. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB et al (2016) Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63(5):575–582

    Article  PubMed  PubMed Central  Google Scholar 

  62. Chua KY, Monk IR, Lin YH, Seemann T, Tuck KL, Porter JL et al (2014) Hyperexpression of alpha-hemolysin explains enhanced virulence of sequence type 93 community-associated methicillin-resistant Staphylococcus aureus. BMC Microbiol 14:31

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Coombs GW, Nimmo GR, Bell JM, Huygens F, O'Brien FG, Malkowski MJ et al (2004) Genetic diversity among community methicillin-resistant Staphylococcus aureus strains causing outpatient infections in Australia. J Clin Microbiol 42(10):4735–4743

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. O'Brien FG, Lim TT, Chong FN, Coombs GW, Enright MC, Robinson DA et al (2004) Diversity among community isolates of methicillin-resistant Staphylococcus aureus in Australia. J Clin Microbiol 42(7):3185–3190

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Hunt C (1999) Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep 48(32):707–710

    Google Scholar 

  66. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S et al (1998) Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279(8):593–598

    Article  CAS  PubMed  Google Scholar 

  67. Otto M (2012) MRSA virulence and spread. Cell Microbiol 14(10):1513–1521

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M et al (2002) Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359(9308):753–759

    Article  CAS  PubMed  Google Scholar 

  69. Genestier AL, Michallet MC, Prevost G, Bellot G, Chalabreysse L, Peyrol S et al (2005) Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. J Clin Invest 115(11):3117–3127

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Colin DA, Monteil H (2003) Control of the oxidative burst of human neutrophils by staphylococcal leukotoxins. Infect Immun 71(7):3724–3729

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Konig B, Prevost G, Piemont Y, Konig W (1995) Effects of Staphylococcus aureus leukocidins on inflammatory mediator release from human granulocytes. J Infect Dis 171(3):607–613

    Article  CAS  PubMed  Google Scholar 

  72. Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D et al (2007) Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 45(3):315–321

    Article  PubMed  Google Scholar 

  73. Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D et al (2006) Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 194(12):1761–1770

    Article  CAS  PubMed  Google Scholar 

  74. Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR (2008) Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 198(8):1166–1170

    Article  PubMed  Google Scholar 

  75. Ellington MJ, Hope R, Ganner M, Ganner M, East C, Brick G, Kearns AM (2007) Is Panton-Valentine leucocidin associated with the pathogenesis of Staphylococcus aureus bacteraemia in the UK? J Antimicrob Chemother 60(2):402–405

    Article  CAS  PubMed  Google Scholar 

  76. Shallcross LJ, Fragaszy E, Johnson AM, Hayward AC (2013) The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 13(1):43–54

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52(3):285–292

    Article  PubMed  Google Scholar 

  78. Fowler VG Jr, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB et al (2003) Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 163(17):2066–2072

    Article  PubMed  Google Scholar 

  79. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB (2012) Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev 25(2):362–386

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr (2015) Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28(3):603–661

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Bai AD, Agarwal A, Steinberg M, Showler A, Burry L, Tomlinson GA et al (2017) Clinical predictors and clinical prediction rules to estimate initial patient risk for infective endocarditis in Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. Clin Microbiol Infect 23(12):900–906

    Article  CAS  PubMed  Google Scholar 

  82. Tande AJ, Palraj BR, Osmon DR, Berbari EF, Baddour LM, Lohse CM et al (2016) Clinical presentation, risk factors, and outcomes of hematogenous prosthetic joint infection in patients with Staphylococcus aureus bacteremia. Am J Med 129(2):221.e211–221.e220

    Article  Google Scholar 

  83. Schmitt SK (2017) Osteomyelitis. Infect Dis Clin N Am 31(2):325–338

    Article  Google Scholar 

  84. Heltshe SL, Khan U, Beckett V, Baines A, Emerson J, Sanders DB et al (2018) Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis. J Cyst Fibros 17(3):341–347

    Article  CAS  PubMed  Google Scholar 

  85. Gangell C, Gard S, Douglas T, Park J, de Klerk N, Keil T et al (2011) Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis 53(5):425–432

    Article  PubMed  Google Scholar 

  86. Janhsen WK, Arnold C, Hentschel J, Lehmann T, Pfister W, Baier M et al (2016) Colonization of CF patients’ upper airways with S. aureus contributes more decisively to upper airway inflammation than P. aeruginosa. Med Microbiol Immunol 205(5):485–500

    Article  CAS  PubMed  Google Scholar 

  87. Foundation CF (2017) Cystic Fibrosis Foundation Patient Registry 2016 Annual Data Report. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2016-Patient-Registry-Annual-Data-Report.pdf.

  88. Foundation CF (2018) Cystic Fibrosis Foundation Patient Registry 2017 Annual Data Report. Bethesda, MD

    Google Scholar 

  89. Dezube R, Jennings MT, Rykiel M, Diener-West M, Boyle MP, Chmiel JF et al (2019) Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. J Cyst Fibros 18(3):357–363. https://doi.org/10.1016/j.jcf.2018.07.005

    Article  CAS  PubMed  Google Scholar 

  90. Goss CH, Muhlebach MS (2011) Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros 10(5):298–306

    Article  CAS  PubMed  Google Scholar 

  91. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP (2010) Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 303(23):2386–2392

    Article  CAS  PubMed  Google Scholar 

  92. Sawicki GS, Rasouliyan L, Pasta DJ, Regelmann WE, Wagener JS, Waltz DA et al (2008) The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol 43(11):1117–1123

    Article  PubMed  Google Scholar 

  93. Vanderhelst E, De Meirleir L, Verbanck S, Pierard D, Vincken W, Malfroot A (2012) Prevalence and impact on FEV(1) decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients. J Cyst Fibros 11(1):2–7

    Article  CAS  PubMed  Google Scholar 

  94. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP (2008) Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 178(8):814–821

    Article  PubMed  Google Scholar 

  95. Wood ME, Sherrard LJ, Ramsay KA, Yerkovich ST, Reid DW, Kidd TJ et al (2016) Methicillin-resistant Staphylococcus aureus acquisition in healthcare workers with cystic fibrosis: a retrospective cross-sectional study. BMC Pulm Med 16(1):78

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  96. Jennings MT, Dasenbrook EC, Lechtzin N, Boyle MP, Merlo CA (2017) Risk factors for persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. J Cyst Fibros 16(6):681–686

    Article  PubMed  Google Scholar 

  97. Cramton SE, Ulrich M, Gotz F, Doring G (2001) Anaerobic conditions induce expression of polysaccharide intercellular adhesin in Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun 69(6):4079–4085

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Besier S, Smaczny C, Von Mallinckrodt C, Krahl A, Ackermann H, Brade V et al (2007) Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol 45(1):168–172

    Article  CAS  PubMed  Google Scholar 

  99. Kahl B, Herrmann M, Everding AS, Koch HG, Becker K, Harms E et al (1998) Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 177(4):1023–1029

    Article  CAS  PubMed  Google Scholar 

  100. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M et al (2006) Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4(4):295–305

    Article  CAS  PubMed  Google Scholar 

  101. Suwantarat N, Rubin M, Bryan L, Tekle T, Boyle MP, Carroll KC et al (2018) Frequency of small-colony variants and antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients. Diagn Microbiol Infect Dis 90(4):296–299

    Article  CAS  PubMed  Google Scholar 

  102. Radlinski L, Conlon BP (2018) Antibiotic efficacy in the complex infection environment. Curr Opin Microbiol 42:19–24

    Article  CAS  PubMed  Google Scholar 

  103. Mainz JG, Naehrlich L, Schien M, Kading M, Schiller I, Mayr S et al (2009) Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis. Thorax 64(6):535–540

    Article  CAS  PubMed  Google Scholar 

  104. Ridder-Schaphorn S, Ratjen F, Dubbers A, Haberle J, Falk S, Kuster P et al (2007) Nasal Staphylococcus aureus carriage is not a risk factor for lower-airway infection in young cystic fibrosis patients. J Clin Microbiol 45(9):2979–2984

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Choi KJ, Cheng TZ, Honeybrook AL, Gray AL, Snyder LD, Palmer SM et al (2018) Correlation between sinus and lung cultures in lung transplant patients with cystic fibrosis. Int Forum Allergy Rhinol 8(3):389–393

    Article  PubMed  Google Scholar 

  106. Shields RK, Clancy CJ, Minces LR, Kwak EJ, Silveira FP, Abdel Massih RC et al (2012) Staphylococcus aureus infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes. J Heart Lung Transplant 31(11):1199–1206

    Article  PubMed  Google Scholar 

  107. Cystic Fibrosis Trust Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK. Cystic Fibrosis Trust

    Google Scholar 

  108. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB et al (2007) Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 176(10):957–969

    Article  CAS  PubMed  Google Scholar 

  109. Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P et al (2014) European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros 13(Suppl 1):S23–S42

    Article  PubMed  Google Scholar 

  110. Solis A, Brown D, Hughes J, Van Saene HK, Heaf DP (2003) Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol 36(3):189–195

    Article  CAS  PubMed  Google Scholar 

  111. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB et al (2013) Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187(7):680–689

    Article  PubMed  Google Scholar 

  112. Stutman HR, Lieberman JM, Nussbaum E, Marks MI (2002) Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 140(3):299–305

    Article  CAS  PubMed  Google Scholar 

  113. Lo DK, Muhlebach MS, Smyth AR (2018) Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev 7:Cd009650

    PubMed  Google Scholar 

  114. Smyth AR, Rosenfeld M (2017) Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 4:CD001912

    PubMed  Google Scholar 

  115. Walkey AJ, O'Donnell MR, Wiener RS (2011) Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 139(5):1148–1155

    Article  CAS  PubMed  Google Scholar 

  116. Fusco NM, Meaney CJ, Wells C, Frederick CA, Prescott WA Jr (2018) Vancomycin versus vancomycin plus rifampin for the treatment of acute pulmonary exacerbations of cystic fibrosis. J Pediatr Pharmacol Ther 23(2):125–131

    PubMed  PubMed Central  Google Scholar 

  117. Muhlebach MS, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N et al (2017) Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax 72(4):318–326

    Article  PubMed  Google Scholar 

  118. Burdge DR, Nakielna E, Noble M (1995) Eradication of methicillin-resistant Staphylococcus aureus from the lower respiratory tract of patients with cystic fibrosis. Can J Infect Dis 6(2):97–101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Doe SJ, McSorley A, Isalska B, Kearns AM, Bright-Thomas R, Brennan AL et al (2010) Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros 9(2):104–109

    Article  CAS  PubMed  Google Scholar 

  120. Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C et al (2004) Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect 56(3):208–214

    Article  CAS  PubMed  Google Scholar 

  121. Wilkinson JD (2008) MRSA in Paediatric Cystic Fibrosis patients, Eradication and Treatment. http://www.clinicalguidelines.scot.nhs.uk/ggc-paediatric-guidelines/ggc-guidelines/microbiology/mrsa-in-paediatric-cystic-fibrosis-patients-eradication-and-treatment/. Accessed 26 Oct 2018

  122. Loening-Baucke VA, Mischler E, Myers MG (1979) A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. J Pediatr 95(4):630–637

    Article  CAS  PubMed  Google Scholar 

  123. Chastre J, Blasi F, Masterton RG, Relio J, Torres A, Welte T (2014) European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 20:19–36

    Article  CAS  PubMed  Google Scholar 

  124. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File JTM, Musher DM, Niederman MS, Torres A, Whitney CG (2007) Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 44(Suppl 2):S27–S72

    Article  CAS  PubMed  Google Scholar 

  125. Roch M, Varela MC, Taglialegna A, Rose WE, Rosato AE (2018) Activity of telavancin against Staphylococcus aureus isolates, including those with decreased susceptibility to ceftaroline, from cystic fibrosis patients. Antimicrob Agents Chemother 62(9):e00956-18

    Article  PubMed  PubMed Central  Google Scholar 

  126. Shirai M, Ide K, Sato M, Murakami M, Tanaka Y, Sato A et al (1995) Effect of inhaled vancomycin hydrochloride on elimination of methicillin-resistant Staphylococcus aureus. Nihon Kyobu Shikkan Gakkai Zasshi 33(11):1233–1239

    CAS  PubMed  Google Scholar 

  127. Kappler M, Nagel F, Feilcke M, Kröner C, Pawlita I, Naehrig S et al (2016) Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: a single center observational study. Pediatr Pulmonol 51(10):1010–1019

    Article  PubMed  Google Scholar 

  128. Hayes D Jr, Murphy BS, Mullett TW, Feola DJ (2010) Aerosolized vancomycin for the treatment of MRSA after lung transplantation. Respirology 15(1):184–186

    Article  PubMed  Google Scholar 

  129. Patrick FA (2018) Phase III, randomized, double-blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus Aureus lung infection in cystic fibrosis patients. Accessed 5 Nov 2018

    Google Scholar 

  130. Zemanick ET, Daines CL, Dellon EP, Esther CR Jr, Kinghorn B, Ong T et al (2017) Highlights from the 2016 north American cystic fibrosis conference. Pediatr Pulmonol 52(8):1103–1110

    Article  PubMed  PubMed Central  Google Scholar 

  131. Zobell JT, Epps KL, Young DC, Montague M, Olson J, Ampofo K et al (2015) Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol 50(6):552–559

    Article  PubMed  Google Scholar 

  132. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ et al (2014) Antibiotic management of lung infections in cystic fibrosis. I. the microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 11(7):1120–1129

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA

    Sarah J. Chalmers & Mark E. Wylam

Authors
  1. Sarah J. Chalmers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark E. Wylam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark E. Wylam .

Editor information

Editors and Affiliations

  1. Department of Veterinary Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN, USA

    Yinduo Ji

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Chalmers, S.J., Wylam, M.E. (2020). Methicillin-Resistant Staphylococcus aureus Infection and Treatment Options. In: Ji, Y. (eds) Methicillin-Resistant Staphylococcus Aureus (MRSA) Protocols. Methods in Molecular Biology, vol 2069. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9849-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9849-4_16

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-9848-7

  • Online ISBN: 978-1-4939-9849-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation